Thanks to all for the kind thoughts... ARIA has patent news>
Business Wire - January 14, 2003 10:28
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 14, 2003--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced the issuance of a U.S. patent covering intramuscular administration of therapeutic genes controlled by ARIAD's cell-signaling regulation technology - the product concept being used in ARIAD's novel erythropoietin (EPO) anemia product candidate. A specially designed, dormant form of the EPO gene is injected into muscle at the onset of treatment, followed by oral administration of ARIAD's patented, small molecule-drug, AP22594, once or twice a month, to increase circulating levels of EPO and red blood cells directly in proportion to the amount of AP22594 administered.
"This newly issued patent further strengthens our intellectual property portfolio for orally regulated protein therapy and specifically covers our novel EPO product candidate to treat anemia. This patent brings together the key elements of regulated protein therapy: our ARGENT technology for gene regulation, our AAV gene delivery vehicle, and the choice of muscle as the site of gene delivery," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. |
